tiprankstipranks
Trending News
More News >
Luxbright AB (SE:LXB)
:LXB
Advertisement

Luxbright AB (LXB) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Luxbright AB

(Frankfurt:LXB)

Rating:37Underperform
Price Target:
Luxbright AB faces significant financial challenges, including ongoing losses and negative cash flows, which pose high financial risk. The technical indicators show a bearish trend, and the absence of profitability impacts valuation negatively. Overall, the stock's outlook is cautious, with a need for strategic improvements to enhance its financial and operational standing.

Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)

Luxbright AB Business Overview & Revenue Model

Company DescriptionLuxbright AB (LXB) is a Sweden-based company that operates in the medical technology sector. The company specializes in the development and manufacturing of innovative X-ray tubes and generators, which are utilized in various applications including healthcare, security, and industrial inspection. Luxbright is dedicated to advancing X-ray technology with its proprietary cold cathode technology, which aims to enhance image quality and reduce radiation exposure.
How the Company Makes MoneyLuxbright AB generates revenue by designing, producing, and selling its advanced X-ray tubes and systems to clients in the healthcare, security, and industrial sectors. The company capitalizes on its unique cold cathode technology, which offers enhanced performance and safety features compared to traditional X-ray systems, attracting a variety of customers looking for cutting-edge solutions. Luxbright may also form strategic partnerships or licensing agreements to expand its market reach and further monetize its proprietary technology. Additionally, the company might receive income from research collaborations and grants aimed at advancing its technological innovations.

Luxbright AB Financial Statement Overview

Summary
Luxbright AB is in a challenging financial position with ongoing losses, despite revenue growth and a strong equity base. The lack of profitability and negative cash flows suggest high financial risk, which may require strategic adjustments to enhance operational efficiency and financial performance.
Income Statement
25
Negative
Luxbright AB has shown significant revenue growth in the most recent year, but the company remains unprofitable with negative EBIT and net income over the past years. The gross profit margin is high at 98.4% for 2024, but the net profit margin is negative due to high operating expenses. The continuous losses are a significant concern despite revenue growth.
Balance Sheet
40
Negative
The company has a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. However, the return on equity (ROE) remains negative due to continued net losses. The equity ratio is stable, showing a solid foundation, but profitability issues weigh on the overall balance sheet health.
Cash Flow
30
Negative
Luxbright AB's operating cash flow and free cash flow are consistently negative, indicating cash burn. The financing cash flow has been positive, suggesting reliance on external funding. The free cash flow to net income ratio is not favorable, highlighting a need for improved cash generation from operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.02M854.70K811.70K729.00K614.29K
Gross Profit8.88M-2.80M189.12K1.98M1.57M
EBITDA-15.72M-24.35M-20.47M-17.63M-12.18M
Net Income-17.72M-25.38M-21.13M-18.10M-12.47M
Balance Sheet
Total Assets42.66M40.69M31.19M23.99M44.11M
Cash, Cash Equivalents and Short-Term Investments12.36M14.04M7.60M7.51M29.51M
Total Debt0.00206.02K588.34K1.10M1.81M
Total Liabilities8.46M7.00M3.33M3.36M5.47M
Stockholders Equity34.20M33.69M27.86M20.63M38.64M
Cash Flow
Free Cash Flow-16.52M-20.39M-20.64M-17.14M-13.67M
Operating Cash Flow-16.52M-20.39M-20.64M-17.14M-13.67M
Investing Cash Flow-3.44M-3.99M-7.15M-4.15M-3.42M
Financing Cash Flow18.28M30.82M27.88M-708.00K40.26M

Luxbright AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
0.73
Negative
100DMA
0.75
Negative
200DMA
0.82
Negative
Market Momentum
MACD
-0.01
Negative
RSI
45.01
Neutral
STOCH
34.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.73, and below the 200-day MA of 0.82, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.01 is Neutral, neither overbought nor oversold. The STOCH value of 34.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.

Luxbright AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
SES2M
61
Neutral
kr11.74M
96.10%94.79%
52
Neutral
kr5.53B11.11-72.81%1.94%25.71%21.63%
47
Neutral
kr83.54M-79.12%86.02%93.34%
42
Neutral
€380.00M-190.21%16.98%79.03%
SELXB
37
Underperform
kr93.97M-51.52%955.20%47.31%
33
Underperform
€44.82M
-63.52%93.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:LXB
Luxbright AB
0.68
-0.38
-35.66%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.26
-2.60
-44.39%
SE:QLIFE
Qlife Holding AB
3.52
2.16
159.40%
SE:QLINEA
Q-linea AB
59.60
-444.10
-88.17%
SE:S2M
S2Medical AB Class B
0.01
-0.02
-59.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025